Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk has established itself as a leading global healthcare company with a strong focus on a range of care categories. Its key business segments include diabetes care, obesity care, hemophilia care, growth hormone therapy, and hormone replacement therapy, addressing the needs of patients with chronic medical conditions.
The company features a prestigious portfolio of brands known for their effectiveness in managing these conditions. NovoLog/NovoRapid (insulin aspart) and Levemir (insulin detemir) are integral to its diabetes care segment. In the fight against obesity, Novo Nordisk offers drugs like Saxenda (liraglutide for obesity). For individuals with hemophilia, NovoSeven (recombinant Factor VIIa) provides critical care, while Norditropin (growth hormone) is a cornerstone of its growth hormone therapy division.
Novo Nordisk's global reach is extensive, with products sold across the world. The United States, China, Japan, and many European countries are key markets, with the United States being particularly vital due to the high prevalence of diabetes and other lifestyle-related diseases. Additionally, Novo Nordisk has a significant presence in emerging markets, expanding its international influence and accessibility to essential medications. (Powered by AI)